4 September 2017
SpeeDx Awarded A$2.5 million by NSW Medical Devices Fund
SpeeDx Pty. Ltd. are among the recipients of the New South Wales Medical Devices Fund (MDF) 2017-2018, announced last night....
9 June 2017
SpeeDx and Cepheid Announce European Distribution Partnership
Strategic commercial partnership in key European markets with Cepheid. SYDNEY, AUSTRALIA--(Marketwired - Jun 8, 2017) - SpeeDx Pty, Ltd., a developer...
26 April 2017
SpeeDx and Thermo Fisher Scientific Strategic Partnership
SpeeDx and Thermo Fisher Scientific Announce Strategic Partnership for FDA Clearance of Molecular Diagnostic. ResistancePlus™ MG Test would bring disease and...
6 April 2017
Prospective Evaluation Study for ResistancePlus® MG
A prospective evaluation study published in the Journal of Clinical Microbiology evaluated our ResistancePlus® MG assay against 1089 symptomatic and asymptomatic...
17 February 2017
Nature Reviews Urology | Growing threat of macrolide resistant M. genitalium infections.
The authors of the review, Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium, published in Nature Review Urology recommended that...
13 February 2017
The Age | Researchers raise concerns over sexually transmitted superbug
This drug-resistant sexually transmitted infection is behaving like a superbug and researchers estimate as many as 400,000 Australians may be...
